Benefits
Capillary Fragility / Bleeding Gum Support
Historical use for capillary fragility, easy bruising, bleeding gums (often combined with vitamin C). Reduces capillary permeability — same mechanism as hesperidin. Long-established clinical positioning.
Venous Insufficiency Adjunct
Rutin (especially as O-(beta-hydroxyethyl)-rutoside / oxerutins / Venoruton®) used for chronic venous insufficiency in Europe. Comparable evidence to hesperidin/diosmin for some indications.
Antioxidant Activity
Direct free radical scavenging plus quercetin-like effects after gut hydrolysis to active aglycone. Broad antioxidant profile contributing to cardiovascular and longevity applications.
Anti-Inflammatory Effects
Inhibits inflammatory cytokine production, reduces NF-κB activation. Modest anti-inflammatory profile.
Mast Cell Protocol Component
Often combined with luteolin and quercetin in MCAS (mast cell activation syndrome) protocols (e.g., NeuroProtek® combinations). Adjunctive to primary mast cell stabilizers.
Mechanism of action
Quercetin Prodrug
Rutin is a glycoside that gets hydrolyzed by gut microbiome to release quercetin (the active aglycone) plus rutinose. Functionally a delayed-release/colon-targeted quercetin source. Bioavailability and tissue distribution differ from free quercetin.
Capillary Permeability Reduction
Decreases capillary leakage — improves capillary integrity. Foundational mechanism for 'bioflavonoid' applications in capillary fragility.
Antioxidant via Free Radical Scavenging
Direct antioxidant activity plus iron-chelating activity. Inhibits lipid peroxidation.
Synergy with Vitamin C
Vitamin C and rutin (and other bioflavonoids) work synergistically — flavonoids stabilize vitamin C by reducing oxidation. Basis for traditional 'vitamin C with bioflavonoids' formulations.
Clinical trials
Multiple RCTs of hydroxyethylrutosides / oxerutins (Venoruton®) for chronic venous insufficiency.
CVI patients across multiple trials.
Oxerutins significantly improve CVI symptoms (edema, pain, leg heaviness). Evidence comparable to MPFF (diosmin/hesperidin). Established treatment in Europe.
Trials of rutin or rutin-containing products for hemorrhoid management.
Hemorrhoid patients.
Modest improvements in bleeding, pain, swelling. Less robust evidence than MPFF (diosmin/hesperidin) but supportive. Reasonable adjunct.